Phase 1 expansion results of IDE397, a first-in-class, oral, MAT2A inhibitor (MAT2Ai) in MTAP deleted(del) non-small cell lung cancer (NSCLC) and urothelial cancer (UC)

被引：0
|
作者：
Herzberg, B. [1 ]
Johnson, M. [2 ]
Kim, C. G. [3 ]
Tolcher, A. [4 ]
Rodon, J. [5 ]
Mantia, C. [6 ]
Liu, J. [7 ]
Tripathi, A. [8 ]
Rodriguez, L. Paz-Ares [9 ]
Rouge, T. De la Motte [10 ]
Choi, C. M. [11 ]
Han, J. Y. [12 ]
Kwei, L. [13 ]
Liu, E. [14 ]
Sachdev, J. [14 ]
O'Quigley, M. [14 ]
White, M. [15 ]
Beaupre, D. [16 ]
Kim, H. R. [17 ]
机构：
[1] Columbia Univ, Dept Hematol & Oncol, Herbert Irving Comprehens Canc Ctr, New York, NY USA
[2] Sarah Cannon Res Inst, SCRI Dev Innovat Div, Nashville, TN USA
[3] Yonsei Canc Ctr, Dept Internal Med, Div Med Oncol, Seoul, South Korea
[4] NEXT Oncol, Clin Res, San Antonio, TX USA
[5] MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Div Canc Med, Houston, TX USA
[6] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Ctr Canc Therapeut Innovat, Dept Med Oncol, Boston, MA USA
[7] St Vincents Hosp Sydney, Med Oncol, Kinghorn Canc Ctr, Darlinghurst, NSW, Australia
[8] City Hope Comprehens Canc Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA USA
[9] Hosp Univ 12 Octubre, Dept Med Oncol, Madrid, Spain
[10] Ctr Eugene Marquis, Dept Med Oncol, Rennes, France
[11] Univ Ulsan, Dept Oncol, Asan Med Ctr, Coll Med, Seoul, South Korea
[12] Natl Canc Ctr, Ctr Lung Canc, Goyang, South Korea
[13] IDEAYA Biosci, Biometr, San Francisco, CA USA
[14] IDEAYA Biosci, Clin Dev, San Francisco, CA USA
[15] IDEAYA Biosci, Res, San Francisco, CA USA
[16] IDEAYA Biosci, Clin Dev, San Diego, CA USA
[17] Yonsei Univ, Yonsei Canc Ctr, Div Med Oncol, Dept Internal Med,Coll Med, Seoul, South Korea
来源：
EUROPEAN JOURNAL OF CANCER | 2024年 / 211卷
关键词：
D O I：
10.1016/j.ejca.2024.114979
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
501LBA
引用
收藏
页码：S176 / S177
页数：2
相关论文
共 50 条
  • [21] A Phase 1b/2 Study of Atezolizumab With or Without Daratumumab in Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
    Pillai, R.
    Ramalingam, S.
    Paz-Ares, L.
    Thayu, M.
    Watson, P.
    Reck, M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2288 - S2288
  • [22] Prospective Phase 1/2 Trial of Carbon Ion Radiation Therapy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
    Takahashi, W.
    Yamamoto, N.
    Nakajima, M.
    Sakumi, A.
    Yamashita, H.
    Nakagawa, K.
    Tsuji, H.
    Kamada, T.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S215 - S215
  • [23] Efficacy and Safety Data From a Phase 1/2 Trial of Tislelizumab in Chinese Patients With Non-Small Cell Lung Cancer (NSCLC)
    Zhou, Q.
    Zhao, J.
    Wang, J.
    Zhang, Q.
    Pan, H.
    Shen, L.
    Yuan, Y.
    Bai, Y.
    Liu, T.
    Gao, Y.
    Li, Y.
    Zhang, J.
    Wu, Y. -L.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S48 - S49
  • [24] A phase 1 study of ramucirumab (R) plus pembrolizumab (P) in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or urothelial carcinoma (UC): Phase 1a results
    Herbst, Roy S.
    Bendell, Johanna C.
    Isambert, Nicolas
    Calvo, Emiliano
    Santana-Davila, Rafael
    Cassier, Philippe
    Perez-Gracia, Jose Luis
    Yang, Jing
    Rege, Jessicca
    Ferry, David
    Mi, Gu
    Chau, Ian
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [25] Phase 1/2 trial of the XPO1 inhibitor selinexor in combination with docetaxel in previously treated, advanced KRAS mutant non-small cell lung cancer (NSCLC)
    von Itzstein, Mitchell S.
    Burns, Timothy F.
    Dowell, Jonathan
    Horn, Leora
    Camidge, David Ross
    York, Sally J.
    Eaton, Keith D.
    Walker, Christopher James
    Zhang, Song
    Gerber, David E.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [26] A phase 1/2 study of the highly selective EGFR inhibitor, BLU-701, in patients with EGFR-mutant non-small cell lung cancer (NSCLC).
    Spira, Alexander I.
    Spigel, David R.
    Camidge, D. Ross
    De langen, Adrianus
    Kim, Tae Min
    Goto, Koichi
    Elamin, Yasir Y.
    Shum, Elaine
    Reckamp, Karen L.
    Rotow, Julia K.
    Goldberg, Sarah B.
    Gadgeel, Shirish M.
    Leal, Ticiana
    Albayya, Faris
    Fitzpatrick, Sarah
    Louie-Gao, Melinda
    Parepally, Jagan
    Zalutskaya, Alena
    Yu, Helena Alexandra
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [27] Activity of BIBW2992, an oral irreversible dual EGFR/HER2 inhibitor, in non-small cell lung cancer (NSCLC) with mutated EGFR
    Spicer, James
    Calvert, Hilary
    Vidal, Laura
    Azribi, Fathi
    Perrett, Rebecca
    Shahidi, Mehdi
    Temple, Graham
    Futreal, Andrew
    De Bono, Johann
    Plummer, Ruth
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S410 - S410
  • [28] Results from a first-in-human phase 1B study of a complement factor H inhibitor (GT103) in patients with non-small cell lung cancer (NSCLC)
    Clarke, Jeffrey Melson
    Stinchcombe, Tom
    Gu, Lin
    Mamdani, Hirva
    Antonia, Scott Joseph
    Simon, George R.
    Sonpavde, Guru P.
    Ready, Neal E.
    Crawford, Jeffrey
    Campa, Michael
    Gottlin, Elizabeth
    Bushey, Ryan
    Herndon, James Emmett
    Patz, Edward
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [29] Cemiplimab, a human monoclonal anti-PD-1, plus radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC): Results from a phase I expansion cohort (EC 2)
    Moreno, V.
    Gil-Martin, M.
    Johnson, M. L.
    Aljumaily, R.
    Criado, P. Lopez
    Northfelt, D. W.
    Crittenden, M.
    Jabbour, S.
    Rosen, L.
    Garrido, P.
    Moron, A. Hervas
    Rietschel, P.
    Mohan, K. K.
    Li, J.
    Stankevich, E.
    Feng, M.
    Lowy, I.
    Fury, M. G.
    ANNALS OF ONCOLOGY, 2018, 29 : 26 - 26
  • [30] Activity and safety of brigatinib (BRG) in patients (pts) with ALK plus non-small cell lung cancer (NSCLC): Phase (ph) 1/2 trial results.
    Langer, Corey J.
    Gettinger, Scott N.
    Bazhenova, Lyudmila
    Salgia, Ravi
    Gold, Kathryn A.
    Rosell, Rafael
    Shaw, Alice Tsang
    Weiss, Glen J.
    Dorer, David J.
    Rivera, Victor M.
    Haluska, Frank G.
    Kerstein, David
    Camidge, D. Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345